

WEEKLY EPIDEMIOLOGICAL REPORT A publication of the Epidemiology Unit

 Ministry of Health

 231, de Saram Place, Colombo 01000, Sri Lanka

 Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk

 Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk

 Web: http://www.epid.gov.lk

Vol. 51 No. 45

02nd - 08th Nov 2024

World AIDS Day 2024: Prioritizing the rights of young people through evidencebased interventions

World AIDS Day 2024, celebrated on December 1st, provides an essential opportunity to reflect on the progress made in the global battle against HIV and highlight the work that remains, particularly in addressing the challenges faced by young people. The theme of the year 2024, "Take the rights path: My health, my right!" emphasizes the critical need to prioritize the rights of adolescents and young adults in efforts to end the AIDS epidemic by 2030. The focus is on the inequalities that continue to obstruct access to essential health services and the need for comprehensive, evidence-based interventions that empower young people to take care of their health.

The importance of addressing HIV among adolescents and young adults:

Adolescents and young adults, aged 10-24 years, continue to be disproportionately affected by HIV, with significant gaps in access to services across the HIV cascade, including prevention, testing, treatment, and care. This vulnerable group faces unique barriers to accessing HIV-related healthcare due to a combination of social, economic, and health system challenges. These barriers include stigma, discrimination, laws, gender inequalities, and inadequate health services tailored to the needs of young people.

In 2023, an estimated 1.5 million adolescents between the ages of 10 and 19 were living with Summary of the global HIV epidemic, 2023

Source: UNAIDS/WHO estimates, 2024

HIV, and 140,000 new infections were reported. Despite ongoing efforts to address these gaps, the global response to HIV remains insufficient, particularly for young people from key populations, such as those living in high-prevalence regions like southern Africa, or those involved in high-risk behaviours. Young women, especially those aged 15-24, are still significantly affected by new HIV infections, making targeted interventions for this group crucial to reversing the epidemic

As scientific evidence on effective HIV prevention, treatment, and care improves, there is a growing recognition that the health needs of adolescents extend beyond HIV to other coinfections, such as tuberculosis (TB), sexually transmitted infections (STIs), and hepatitis B and C. Integrated and evidence-based approaches are necessary to meet the comprehensive health needs of this age group.

An evidence-based approach to HIV prevention and care for young people

The World Health Organization (WHO) has been at the forefront of promoting a comprehensive and integrated approach to HIV prevention and care.

	People living	People	People dying from
	with HIV	acquiring HIV	HIV-related causes
Zee Total	39.9 million	1.3 million	630 000
	[36.1–44.6 million]	[1.0–1.7 million]	[500 000-820 000]
Adults (15+ years)	38.6 million	1.2 million	560 000
	[34.9–43.1 million]	[950 000–1.5 million]	[430 000–730 000]
🖉 Women (15+ years)	20.5 million	520 000	240 000
	[18.5–22.9 million]	[400 000–690 000]	[180 000-320 000]
A Men (15+ years)	18.1 million	660 000	320 000
	[16.2–20.3 million]	[540 000-840 000]	[250 000-420 000]
Children (<15 years)	1.4 million	120 000	76 000

Page
1
4

RI LANKA 2024

WER Sri Lanka - Vol. 51 No. 45

In the context of World AIDS Day 2024, WHO launched a new technical document outlining evidence-based interventions and recommendations for HIV prevention, testing, treatment, and care, with a particular focus on adolescents and young adults. This document highlights the importance of combination prevention programs that use a mix of biomedical, behavioural, and structural interventions to address the unique needs of this group.

WHO emphasizes that interventions must be practical, sustainable, and context-specific to be effective. To this end, the document prioritizes those interventions that are most likely to improve health outcomes for adolescents and young people. It provides a comprehensive set of recommendations to guide healthcare providers, policymakers, and program managers in implementing interventions that have proven to be effective in addressing the challenges faced by adolescents and young adults living with HIV.

Key recommendations include expanding access to HIV testing and treatment services, ensuring that HIV services are adolescent-friendly, and integrating HIV care with services addressing other health issues, such as mental health and sexual and reproductive health. The WHO guideline emphasizes the importance of peer-driven, adolescent-friendly health services, which are shown to improve engagement and treatment outcomes for young people.

The role of peer-driven, adolescent-friendly health services

Meaningful engagement of young people is critical to achieving better health outcomes. It is important to have peer-driven initiatives, where young people play an active role in their care and the design and implementation of health services. This approach is effective in ensuring the acceptance of quality HIV services among adolescents and young adults.

The engagement of young people in their care goes beyond treatment; it involves empowering them to take leadership roles in their health journey. This includes engaging them in advocacy for their health rights, facilitating peer education, and supporting them in accessing HIV prevention, treatment, and care services in a way that aligns with global standards and best practices.

Peer support networks and community-based outreach also play an important role in reducing the stigma surrounding HIV and encouraging young people to seek the care they need. Stigma remains one of the biggest barriers to HIV care for adolescents, particularly in regions where cultural norms and gender inequalities make it difficult for young people to discuss sexual and reproductive health issues openly. By involving peers in the process, young people are more likely to feel comfortable accessing services and receiving support from others who understand their experiences.

HIV testing and treatment for children and adolescents

While the focus on HIV in young people often emphasizes prevention, testing and treatment are also crucial. An estimated 1.4 million children aged 0-14 were living with HIV at the end of 2023, with 120,000 new infections and 76,000 deaths from AIDS-related illnesses. WHO emphasizes the urgent need for early testing and treatment to reduce HIV-related mortality and morbidity among children.

WHO recommends that infants born to mothers living with HIV be tested for HIV by two months of age and that they continue to be tested during breastfeeding. Early diagnosis and the initiation of antiretroviral therapy (ART) are essential for ensuring that children living with HIV have the best chance of surviving into adulthood. However, despite the clear need, access to ART remains insufficient for children, with only 57% of children receiving ART in 2023 compared to 77% of adults. The lack of child-friendly formulations of antiretroviral drugs further exacerbates this issue.

Adolescents living with HIV also face challenges in accessing treatment and maintaining adherence to ART. The unique developmental needs of adolescents, coupled with the stigma and discrimination they often face, make it harder for them to engage with healthcare services consistently. WHO stresses the importance of adolescent-friendly health services to improve access to HIV care and ensure that treatment is tailored to the specific needs of this age group. This includes offering services that address the social and psychological challenges faced by adolescents living with HIV.

Addressing the wider health needs of adolescents and young adults

The needs of adolescents and young adults go beyond HIV, and as such, several other health conditions disproportionately affect this group, such as TB, STIs, and hepatitis. The relationship between HIV, TB, and STIs emphasizes the need for integrated care models that address these co-infections together.

HIV-related services must be part of a broader, person-centred approach to adolescent health that includes mental health support, sexual and reproductive health services, and education on healthy lifestyles. Addressing the psychosocial aspects of living with HIV is particularly important, as mental health issues such as depression and anxiety are common among adolescents living with the virus.

Compiled by:

Dr Aruni Hathamuna Senior Registrar Epidemiology Unit

References:

- 1. Treatment and care in children and adolescents. <u>www.who.int. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/treatment-and-care-in-children-and-adolescents</u>
- 2. World AIDS Day 2024.(2024). Who.int.
- https://www.who.int/campaigns/world-aids-day/2024
 WHO (2024, December 2) World AIDS Day 2024: prioritizing the rights of young people through evidence-based interventions. Who.int; World Health Organization: WHO. https://www.who.int/news/item/02-12-2024-world-aids-day-2024--prioritizing-the-rights-of-young-people-through-evidence-based-interventions
- 4. World Health Organization. (2024). Implementing WHO evidence-based interventions for adolescents and young adults living with and at risk of HIV. World Health Organization.

https://iris.who.int/bitstream/ handle/10665/379634/9789240100411-eng.pdf? sequence=1

WER Sri Lanka -	Vol. 51	No. 45
VV LAL SII Lalika -		

02nd-08th Nov 2024

Tab	le 1	: Se	elec	ted	noti	ifiab	le d	lisea	ases	s rei	oort	ed k	ov M	edi	cal (Offic	cers	s of	Hea	lth	26 th	-01	st N	ov 2	024	(44	1 th V	Veel	k)
	*	100	100	100	100	100	100	100	100	100	603	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	6	7
WRCD	Ŭ *–	94 1	67 1	100 1	96 1	100 1	100 1	100 1	85 1	82 1	100	100 1	100 1	100 1	83 1	100 1	100 1	100 1	100 1	92 1	96 1	100 1	94 1	82 1	100 1	100 1	100 1	95	
osis	В	1852	1008	494	538	110	240	390	131	146	229	25	56	34	30	141	105	105	431	190	251	96	219	118	335	320	130	7658	
Tuberculosis	A	33	, ,	0	10	2	9	5	0	0	2	0	0	0	0	7	0	0	7	4	8	5	9	12	20	7	4	150 7	
	В	2	26	2	55	334	-	4	443	106	~	2	~	10	13	4	22	18	572	35	790	455	41	229	159	27	0	3352 '	
Leishmania-	A	0	-	0	0	26	0	0	2	2	0	-	0	0	0	0	0	0	,	-	Ť	ŝ	2	2	6	-	0	77 3	
	В	42	128	60	13	22	18	86	28	71	31	9	5	24	2	45	36	22	253	72	58	30	37	94	128	73	19	406	
Meningitis	A	0	e	с	0	2	-	4	0	-	-	0	0	0	0	0	0	0	œ	0		0	0	0	9	5	0	37 1	
xodu	в	508	416	587	365	137	242	739	283	333	204	13	10	41	თ	141	118	89	545	123	264	139	341	156	337	803	216	7159	
Chickenpox	A	ω	10	15	4	~	14	13	2	5	0	~	0	0	0	7	2	7	19	2	2	4	0	4	5	19	7	155	
H. Rabiies	в	0	0	~	e	0	0	~	2	0	~	2	0	0	2	2	~	0	4	~	~	-	0	-	N	~	0	26	
H. R	۲	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Viral Hep.	В	0			12	00	6		7	24	7	0	~	4	0	23	9	n	00	4	14	56	49	54	29	13	4	377	
Vir	A	0	0	0	-	0	0	<u> </u>	0	~	0	0	0	0	0	0	~	0	0	0	0	2	4	4	~	-	0	16	
Typhus F.	Ξ	8	11	8	34	9	42	114) 47	28	484	11	13) 5	11	3	2) 12	38	238	31	0	3 46	31	31	31	5	1092	
Τy	۲	0	0	0	~	0	~	2	0	~	2	0	0	0	0	~	0	0	œ	2	~	0	с С	0	~	~	0	29	
ptospirosis	в	474	767	769	232	96	158	821	434	515	22	20	27	100	68	70	176	138	704	238	399	242	455	607	1808	721	67	10127	
Lepto	A	12	19	29	S	c	3	29	2	15	4	0	0	2	0	0	2	0	86	1	5	c	2	10	79	29	0	354	
F. Poisoning	в	23	77	38	59	28	208	103	48	29	47	0	9	22	18	64	23	-	351	S	43	32	58	86	32	14	29	1454	
F. Poi	۲	~	0	~	0	~	0	2	0	~	0	0	0	0	0	0	0	0	0	0	0	~	2	0	~	0	~	11	
En. Fever	ш	49	14	37	0	8	7	12	9	2	27	2	~	0	0	7	0	ო	က	S	2	~	œ	ო	6	10	2	231	
En.	۲	0	0	~	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	
Encephalitis	в	<u>-</u>	35	2	9	2	7	22	4	9	2	0	0	~	0	15	4	~	36	4	7	c	10	5	10	10	0	203	
Ence	۲	0	0	0	~	~	0	0	0	0	0	0	0	0	0	0	0	0	~	0	~	0	~	0	2	0	0	7	
Dysentery	в	36	39	31	34	17	135	49	28	-	63	17	15	13	6	117	34	16	48	11	33	26	38	19	110	26	17	992	
Dys	۲	~	0	~	0	0	5	N	0	0	~	0	~	0	0	~	~	0	~	0	0	0	2	0	4	0	0	20	
Fever	в	10034	4787	2476	4019	777	325	1886	769	1048	5319	295	299	172	207	1473	243	653	2063	1052	684	360	782	869	2570	1821	684	45667	
Dengue Fever	A	141	103	40	66	35	9	26	10	18	30	с	5	-	~	9	0	0	30	21	0	ო	10	26	61	00	~	669	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Table 2: Vaccine-Preventable Diseases & AFP

02nd – 08th Nov 2024

26th -01st	Nov 2024	(44 th Week)
------------	----------	-------------------------

Disease	No. of Cases by Province										Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	Ν	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	02	00	00	00	00	00	00	00	00	02	01	65	80	-18.8%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	01	03	00	00	00	00	01	00	01	03	02	246	208	18.2 %	
Measles	01	01	00	00	00	00	00	00	00	02	20	289	697	-58.5 %	
Rubella	00	00	00	00	00	00	00	00	00	00	01	02	09	-77.8%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	02	0 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	06	-16.6 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	11	02	450 %	
Whooping Cough	00	00	01	00	01	00	01	00	00	00	00	59	07	742.8 %	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, NT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10